| ²é¿´: 346 | »Ø¸´: 0 | |||
chemchenweͳæ (СÓÐÃûÆø)
|
[½»Á÷]
PI3Kgammar/deltaÑо¿·½Ãæ×îºÃµÄ¹«Ë¾ Intellikine ÉÏÖܱ»ÈÕ±¾ÎäÌïÊÕ¹º
|
| In July 2010, Intellikine announced a collaborative partnership with Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), an innovative drug discovery and development company, under which Infinity obtained global development and commercialization rights to Intellikine¡¯s portfolio of inhibitors of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K). Among these inhibitors is IPI-145, an orally available PI3K¦Ä/¦Ã inhibitor which entered clinical study in October 2011. |
» ²ÂÄãϲ»¶
ũҵ×ÊÔ´Óë»·¾³¡¢ÖÇ»Ûũҵרҵ±¾¿ÆÉú±ÏÒµÂÛÎÄ¿ÎÌâÑ¡ÌâÇóÖú
ÒѾÓÐ1È˻ظ´
È˹¤ÖÇÄܸ³ÄܾۺÏÎï¼°¸´ºÏ²ÄÁÏÄ£ÐÍÓ¦ÓÃÓëʵ¼ù
ÒѾÓÐ0È˻ظ´
Ò©ÎïѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ116È˻ظ´
¸÷¹úºÍ¹ú¼Ê×éÖ¯ÏÖÐÐÒ©µä×¢ÉäÓÃË®ÖÊÁ¿±ê×¼
ÒѾÓÐ0È˻ظ´
ÇóÖúÓÃ΢Æ×Êý¾Ý¿â²éѯ
ÒѾÓÐ0È˻ظ´
¼ÆË㻯ѧÓëÈ˹¤ÖÇÄÜÇý¶¯µÄMOFsÐÔÄÜÔ¤²âÓëɸѡ¼¼Êõ
ÒѾÓÐ0È˻ظ´
ÑÐÈýʵÑéÇóÖ¸µ¼
ÒѾÓÐ0È˻ظ´
½ðÊô²ÄÁ϶à³ß¶È¼ÆËãÄ£Äâ¼¼ÊõÓëÓ¦ÓãºÎ¢¹Û»úÀíµ½ºê¹ÛÐÔÄܵɹ¤×÷
ÒѾÓÐ0È˻ظ´
½Î÷¿Æ¼¼Ê¦·¶´óѧ07ÉúÎïѧºÍ08ÉúÎïÓëÒ½Ò©´óÁ¿µ÷¼Á
ÒѾÓÐ26È˻ظ´
¡¾ÕÐÆ¸¡¿Çå±±£¨¼ÃÄÏ£©ÉúÎï¿Æ¼¼ÕÐÆ¸AIÖÆÒ©Ñз¢¼ÆËãÈ˲Å
ÒѾÓÐ18È˻ظ´
100701ҩѧרҵÕе÷¼Á£¬5¸öÃû¶î£¬Ò©Îﻯѧרҵ£¬Ö÷ÒªÊÇÌìȻҩÎﻯѧ·½Ïò¼ÓÒ©Àí
ÒѾÓÐ4È˻ظ´
ÕÒµ½Ò»Ð©Ïà¹ØµÄ¾«»ªÌû×Ó£¬Ï£ÍûÓÐÓÃŶ~
[ͼ˵¶þÕ½]ÈÕ±¾µÛ¹úµÄÏÝÂä
ÒѾÓÐ6È˻ظ´
ÉϺ£¹¤ÒµÑо¿Ôº¿¼²©
ÒѾÓÐ7È˻ظ´
ÖÆÒ©¹¤³ÌµÄ¹¤³Ì·½ÃæºÃ»¹ÊÇÖÆ¼Á·½ÃæºÃ£¿
ÒѾÓÐ16È˻ظ´
¹â´ß»¯·½Ãæ ºÃͶµÄÆÚÐÌ
ÒѾÓÐ8È˻ظ´
ÇóÖú°¡ÇóÖú£¬ÈÕ±¾ÈË΢ÉúÎï¼ì²â¸ãµÄÔõôÑù
ÒѾÓÐ3È˻ظ´
Çó·ÒëÈÕÓïһС¶Î»°£¨ÓлúºÏ³É·½Ã棩
ÒѾÓÐ2È˻ظ´
¡¾ÌÖÂÛ¡¿ÕæÐÄÇë½Ì£ºÈÕ±¾½ÌÊÚÃæÊÔ»áÎÊЩʲô£¿
ÒѾÓÐ16È˻ظ´
¡¾ÇóÖú¡¿¸ß˹¼ÆËã³öÏÖFatal Problem: The smallest alpha delta epsilon is -0.785373
ÒѾÓÐ7È˻ظ´
¿ÆÑдÓСľ³æ¿ªÊ¼£¬ÈËÈËΪÎÒ£¬ÎÒΪÈËÈË














»Ø¸´´ËÂ¥
µã»÷ÕâÀïËÑË÷¸ü¶àÏà¹Ø×ÊÔ´